. 2020 Jul 22;9(18):6473–6484. doi: 10.1002/cam4.3320

TABLE 5.

Selected studies discussing high‐risk PCa group after RP

References	Age group	High‐risk	Comments
Song [23]	≤50/>50	D’Amico risk group	≤50 group: trend of worse BCR‐free survival in H‐risk after matching (KM, P = .073)
Song [23]	≤50/>50	D’Amico risk group	Comparable BCR‐free survival in L‐risk and M‐risk group
Sheng [28]	<50/≥50	Non‐metastatic cT3‐4	<50 group: significant higher PCSM (MV, P = .048) in LAPC patients
Gielchinsky [29]	<50	D’Amico risk group	<50 group: BCR rate at 5y in H‐risk (23.3%) lower than matched older group
Briganti [18]	≤59/60‐64/65‐69/≥70	PSA > 20/cT ≥ 3/bxGS > 7	≤59 group with no comorbidities: CSM was the leading cause of death
Briganti [18]	≤59/60‐64/65‐69/≥70	PSA > 20/cT ≥ 3/bxGS > 7	OCM was the leading cause of death in all patient groups
Hong [40]	<60/≥60	D’Amico risk group	<60 group: lower BCR‐free survival in H‐risk(KM, P = .017)
Hong [40]	<60/≥60	D’Amico risk group	Independent worse BCR‐free survival in H‐risk(MV, P = .001)
Lin [19]	35‐44/45‐54/55‐64/65‐74	pT ≥ 3&GS > 7	35‐44 group: with highest risk of OS and PCSM (MV, P < .05)
Siddiqui [43]	<55/55‐59/60‐64/65‐69/≥70	GPSM (9‐16)	<55 group: significant lower sPFS comparing other groups (P = .041)

GPSM, mayo clinic grade based on GS; H, High risk; L, Low risk; LAPC, locally advanced prostate cancer; M, intermedium risk; MV, multivariate analysis; PSA, SVI, PSM; sPFS, systemic progression‐free survival; UV, univariate analysis.